A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)

Exclusion Criteria

• •Any prior treatment with etrolizumab or other anti-integrin agents (including natalizumab, vedolizumab, and efalizumab)
• •Any prior treatment with anti-mucosal addressin cell adhesion molecule 1 (anti-MAdCAM-1) agents
• •Any prior treatment with rituximab
• •Received intravenous corticosteroids within 30 days prior to Screening
• •Use of agents that deplete B or T cells (e.g., alemtuzumab, rituximab, or visilizumab) within 12 months prior to randomization
• •Any prior immunosuppressive agents (including cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil)
• •Chronic nonsteroidal anti-inflammatory drug (NSAID) use
• •Use of any prescription medications/products within 14 days prior to Check in (Day -1)
• •History of demyelinating disease
• •Neurological conditions or diseases
• •History of cancer
• •History of alcoholism or drug addiction within less than (\<) 1 year prior to Screening
• •History of active or latent tuberculosis (TB), regardless of treatment history
• •History of recurrent opportunistic infections and/or history of severe disseminated viral infections
• •Positive for human immunodeficiency virus (HIV) antibody
• •Any current or recent signs or symptoms of infection
• •Pregnant or lactating
• •Hospitalized within 4 weeks prior to and during Screening
• •History of organ transplant
• •Presence of skin rash at Screening or history of other skin disorders
• •Tattoos, scars, chronic rashes, or sunburn in the area of the designated injection site